Pharmacokinetic interaction between diltiazem and amiodarone in the dog
β Scribed by Joseph Ben David; Meir Bialer
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 312 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
The pharmacokinetic interaction between diltiazem and amiodarone was investigated in dogs. In the presence of amiodarone, diltiazem's AUC values were sigmfkantly increased and its total body clearance and volume of distribution at steady-state significantly decreased. This study indicates that cardiac patients on combined diltiazem-amiodarone therapy may indeed be in a high risk situation in regards to the unexpectedly high blood levels of diltiazem induced: with the ultimate introduction of such side-effects as (1) the lowering of blood pressure, (2) A/V block, and (3) sinus node depression. Such cases would require immediate dosage adjustment.
Assuming that the data obtained in this study can be extrapolated to humans, a patient's physiological parameters should be monitored at periodic intervals and, more importantly, the patient should report the first sign of any untoward effect.
π SIMILAR VOLUMES
Gastrointestinal distress resulting from drug intake is often remedied by administering the drug with antacids. However, antacids have been shown to modify the absorption and excretion of many drugs. This study was designed to delineate the effects of aluminium and magnesium hydroxide antacid suspen
## Abstract In order to determine the potential pharmacokinetic drug interaction between ranitidine and diltiazem (DTZ), each of ten male beagle dogs, age 2Β·7β4Β·0 years, weight 13β16 kg, received a single oral dose of sustained release DTZ with and without previous multiple oral doses of ranitidine
## Abstract __Objective.__ To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers. __Methods.__ Ten healthy male volunteers were assigned into a 2βsequence, 3βperiod pharmacokinetic interaction study. In phase 1, all subjects were randomly a